Are the benefits of aspirin in colorectal cancer limited to PIK3CA mutated cancers?

Speaker: Alberto Sobrero

Alberto Sobrero provides a critical analysis of evidence currently available that mutations in the PIK3CA Gene in colorectal cancer might identify patients that receive greater benefit from aspirin in the adjuvant setting.

Discussion Points

  • Evidence of the benefits of aspirin in colorectal cancer
  • Molecular predictors of drug efficacy
  • How to move forward?